vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Planet Labs PBC（PL）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Planet Labs PBC的1.9倍（$156.4M vs $81.3M），Planet Labs PBC同比增速更快（32.6% vs 7.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 17.5%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Planet Labs PBC（常简称为Planet）是总部位于美国加利福尼亚州旧金山的上市地球影像企业，核心目标是实现全球范围的每日成像，以此监测地表变化、精准识别相关趋势，为多行业的地理数据分析需求提供可靠的数据支持。
BCRX vs PL — 直观对比
营收规模更大
BCRX
是对方的1.9倍
$81.3M
营收增速更快
PL
高出25.1%
7.5%
两年增速更快
BCRX
近两年复合增速
17.5%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $81.3M |
| 净利润 | — | $-59.2M |
| 毛利率 | — | 57.3% |
| 营业利润率 | 13.6% | -22.6% |
| 净利率 | — | -72.8% |
| 营收同比 | 7.5% | 32.6% |
| 净利润同比 | — | -194.7% |
| 每股收益（稀释后） | $0.00 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXPL
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $81.3M | ||
| Q3 25 | $159.4M | $73.4M | ||
| Q2 25 | $163.4M | $66.3M | ||
| Q1 25 | $145.5M | $61.6M | ||
| Q4 24 | $131.5M | $61.3M | ||
| Q3 24 | $117.1M | $61.1M | ||
| Q2 24 | $109.3M | $60.4M |
净利润BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $-59.2M | ||
| Q3 25 | $12.9M | $-22.6M | ||
| Q2 25 | $5.1M | $-12.6M | ||
| Q1 25 | $32.0K | $-35.2M | ||
| Q4 24 | $-26.8M | $-20.1M | ||
| Q3 24 | $-14.0M | $-38.7M | ||
| Q2 24 | $-12.7M | $-29.3M |
毛利率BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 57.3% | ||
| Q3 25 | 98.6% | 57.6% | ||
| Q2 25 | 98.3% | 55.2% | ||
| Q1 25 | 96.9% | 62.1% | ||
| Q4 24 | 95.4% | 61.2% | ||
| Q3 24 | 97.3% | 52.9% | ||
| Q2 24 | 98.4% | 52.4% |
营业利润率BCRXPL
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | -22.6% | ||
| Q3 25 | 18.6% | -24.5% | ||
| Q2 25 | 18.2% | -34.4% | ||
| Q1 25 | 14.6% | -31.5% | ||
| Q4 24 | -3.4% | -36.9% | ||
| Q3 24 | 6.6% | -64.8% | ||
| Q2 24 | 8.0% | -57.2% |
净利率BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | -72.8% | ||
| Q3 25 | 8.1% | -30.8% | ||
| Q2 25 | 3.1% | -19.1% | ||
| Q1 25 | 0.0% | -57.1% | ||
| Q4 24 | -20.4% | -32.8% | ||
| Q3 24 | -12.0% | -63.3% | ||
| Q2 24 | -11.6% | -48.5% |
每股收益（稀释后）BCRXPL
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $-0.19 | ||
| Q3 25 | $0.06 | $-0.07 | ||
| Q2 25 | $0.02 | $-0.04 | ||
| Q1 25 | $0.00 | $-0.12 | ||
| Q4 24 | $-0.13 | $-0.07 | ||
| Q3 24 | $-0.07 | $-0.13 | ||
| Q2 24 | $-0.06 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $443.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $349.6M |
| 总资产 | $465.1M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXPL
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $443.3M | ||
| Q3 25 | $212.9M | $181.1M | ||
| Q2 25 | $260.0M | $133.5M | ||
| Q1 25 | $295.1M | $118.0M | ||
| Q4 24 | $320.9M | $139.0M | ||
| Q3 24 | $96.8M | $148.3M | ||
| Q2 24 | $78.4M | $107.4M |
股东权益BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $349.6M | ||
| Q3 25 | $-387.9M | $435.7M | ||
| Q2 25 | $-421.6M | $444.8M | ||
| Q1 25 | $-451.9M | $441.3M | ||
| Q4 24 | $-475.9M | $464.6M | ||
| Q3 24 | $-468.6M | $473.2M | ||
| Q2 24 | $-475.6M | $500.3M |
总资产BCRXPL
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.1B | ||
| Q3 25 | $446.4M | $696.4M | ||
| Q2 25 | $457.2M | $658.4M | ||
| Q1 25 | $480.0M | $633.8M | ||
| Q4 24 | $490.4M | $630.8M | ||
| Q3 24 | $491.3M | $658.4M | ||
| Q2 24 | $472.4M | $674.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $28.6M |
| 自由现金流经营现金流 - 资本支出 | — | $1.9M |
| 自由现金流率自由现金流/营收 | — | 2.3% |
| 资本支出强度资本支出/营收 | — | 32.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $40.7M |
8季度趋势，按日历期对齐
经营现金流BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $28.6M | ||
| Q3 25 | $41.6M | $67.8M | ||
| Q2 25 | $41.3M | $17.3M | ||
| Q1 25 | $-27.5M | $-6.3M | ||
| Q4 24 | $-5.2M | $4.1M | ||
| Q3 24 | $8.2M | $-7.9M | ||
| Q2 24 | $-1.4M | $-4.3M |
自由现金流BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $1.9M | ||
| Q3 25 | $40.3M | $47.5M | ||
| Q2 25 | $41.1M | $9.2M | ||
| Q1 25 | $-27.7M | $-17.9M | ||
| Q4 24 | $-5.9M | $-3.6M | ||
| Q3 24 | $8.2M | $-23.0M | ||
| Q2 24 | $-1.5M | $-14.2M |
自由现金流率BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 2.3% | ||
| Q3 25 | 25.3% | 64.7% | ||
| Q2 25 | 25.2% | 13.9% | ||
| Q1 25 | -19.0% | -29.1% | ||
| Q4 24 | -4.5% | -5.8% | ||
| Q3 24 | 7.0% | -37.6% | ||
| Q2 24 | -1.4% | -23.6% |
资本支出强度BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 32.9% | ||
| Q3 25 | 0.8% | 27.6% | ||
| Q2 25 | 0.1% | 12.3% | ||
| Q1 25 | 0.1% | 18.9% | ||
| Q4 24 | 0.5% | 12.5% | ||
| Q3 24 | 0.1% | 24.8% | ||
| Q2 24 | 0.1% | 16.4% |
现金转化率BCRXPL
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
PL
| Defense And Intelligence | $49.4M | 61% |
| Civil Government | $18.8M | 23% |
| Commercial | $13.1M | 16% |
